Shots:

• The P-III CheckMate-816 study involves assessing Opdivo (360mg) + CT (q3w for 3 doses) vs CT- followed by surgery as a neoadjuvant treatment in 358 patients with resectable stage Ib to IIIa NSCLC
• The study met its 1EPs- i.e. improvement in pCR (24% vs 2.2%) and showed improvement in 2EPs i.e. MPR (36.9% vs 8.9)- patients who underwent surgery showed that Opdivo did not decrease the feasibility of performing surgery (83% vs 75%)- patients whose tumors were R0 (83% vs 78%)
• Opdivo-based treatments showed benefits in 4 P-III clinical trials in early-stage cancers- including lung cancer- bladder cancer- esophageal/GEJ cancer and melanoma

  Ref: Businesswire | Image: BMS